uniclin chamber presentation
TRANSCRIPT
![Page 1: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/1.jpg)
![Page 2: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/2.jpg)
![Page 3: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/3.jpg)
Muhammad Asad Sardar
Group Brand Manager
![Page 4: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/4.jpg)
![Page 5: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/5.jpg)
WHAT IS UNIVERSALLY ACCLAIMED?
![Page 6: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/6.jpg)
UNICLIN-Introduction:
• Broad-spectrum
• Semi-synthetic Antibiotic
• Bactericidal Antibiotic
• Clindamycin is in a same class of
medications called Lincosamides.
• It works by slowing or stopping the
growth of bacteria.
![Page 7: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/7.jpg)
MODE OF ACTION:
• Lincosamides prevent bacteria
replicating by interfering with the
synthesis of proteins.
• They bind to the 23s portion of the 50S
subunit of bacterial ribosomes and cause
premature dissociation from the
ribosome.
![Page 8: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/8.jpg)
![Page 9: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/9.jpg)
DO LINCOSAMIDES REACT WITH
HUMAN CELLS?
• Lincosamides do not interfere with
protein synthesis in human cells (or those
of other eukaryotes) because human
ribosomes are structurally different from
those of bacteria.
![Page 10: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/10.jpg)
SIDE EFFECTS:
More common• Abdominal or stomach cramps and pain
• Abdominal tenderness
• Diarrhea (watery and severe), which may also be bloody
• Fever
Less common• Sore throat and fever
• Skin rash, redness, and itching
• Unusual bleeding
![Page 11: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/11.jpg)
IN PREGNANCY:
• Clindamycin has been assigned to pregnancy category B by the FDA (Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.)
• Clindamycin has been used during pregnancy and labor and delivery without adverse effects in the fetus or neonate.
• Clindamycin is only recommended for use during pregnancy when benefit outweighs risk.
![Page 12: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/12.jpg)
IN NURSING MOTHER:
• A Concentrations of 0.7 to 3.8 mcg/mL of Clindamycin have been reported into human milk.
• Adverse gastrointestinal effects have been reported in one nursing infant exposed to multiple drugs including Clindamycin.
• Due to the potential for adverse effects in neonates, a decision should be made to discontinue nursing or discontinue the drug.
![Page 13: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/13.jpg)
Date Presentation title 13
![Page 14: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/14.jpg)
• The penicillins have historically been used
as the first-line therapy in Odontogenic
Infections, but increasing rates of resistance
have lowered their usefulness.
• Clindamycin is an attractive first-line
therapy in the treatment of Odontogenic
infections.
![Page 15: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/15.jpg)
Date Presentation title 15
![Page 16: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/16.jpg)
Date Presentation title 16
![Page 17: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/17.jpg)
Date Presentation title 17
![Page 18: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/18.jpg)
Date Presentation title 18
![Page 19: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/19.jpg)
FEATURES & BENEFITS:
• Excellent Penetration
• Lower MICs
• Safe & Tolerable
• Quality with Economy
• Simple & Convenient Dosage
![Page 20: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/20.jpg)
![Page 21: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/21.jpg)
PSEUDOMEMBRANOUS COLITIS
• Pseudomembranous colitis is infection of the large intestine (colon) with an overgrowth of Clostridium difficile bacteria***.
• The Clostridium difficile bacteria is normally seen in the intestine. However, it may overgrow when you take antibiotics. The bacteria release a powerful toxin that causes the lining of the colon to become inflamed and bleed***.
• The most common antibiotics associated with this condition are ampicillin, clindamycin, fluoroquinolones, and cephalosporin***.
![Page 22: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/22.jpg)
Incidence:• Incidence rates for clindamycin-induced
pseudomembranous colitis are reported as 0.1% to 10%*
• The results suggest that the risks associated with the use of Clindamycin are acceptable if the drug is given for the approved specific indications.**
• Pseudomembranous colitis is rare in infants younger than 12 months old and uncommon in children***.
**Med J Aust. 1977 Feb 19;1(8):243-6
![Page 23: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/23.jpg)
Take medication before half an hour of meal with full glass of
water.
![Page 24: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/24.jpg)
References:
*Infectious Diseases in Children, January 2005
**Med J Aust. 1977 Feb 19;1(8):243-6
***Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.
***Gerding DN, Johnson S. Clostridial infections. In: Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 304.
***Thielman NM, Wilson KH. Antibiotic-associated colitis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2009:chap 96.
Date Presentation title 24
![Page 25: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/25.jpg)
![Page 26: UNICLIN Chamber Presentation](https://reader034.vdocuments.site/reader034/viewer/2022051521/5a654b977f8b9aff1a8b48df/html5/thumbnails/26.jpg)